Deutsche Bank maintains a Hold rating on Noven Pharmaceuticals (Nasdaq: NOVN) and lowers its price target from $13 to $12.
This article: 117 words
-->

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE